Physiomics Secures New Contract with Numab Therapeutics for Cancer Treatment Development

Physiomics ( (GB:PYC) ) has shared an update.

Physiomics plc has secured a new contract with Numab Therapeutics AG to apply modelling and simulation techniques in the pre-clinical development of a multi-specific antibody aimed at activating anti-tumor immune responses for cancer treatment. This collaboration underscores Physiomics’ role as a trusted partner in drug development, enhancing its industry positioning and reinforcing its long-term relationship with Numab Therapeutics.

Spark’s Take on GB:PYC Stock

According to Spark, TipRanks’ AI Analyst, GB:PYC is a Underperform.

Physiomics faces significant financial and technical challenges, with declining revenues and bearish technical signals. While recent corporate events indicate potential future growth, current valuation concerns and financial instability weigh heavily on its stock score.

To see Spark’s full report on GB:PYC stock, click here.

More about Physiomics

Physiomics plc is a leading company in mathematical modelling, data science, and biostatistics, focusing on the development of new therapeutics and personalized medicine solutions. The company leverages its expertise in Modelling & Simulation, Biostatistics, Data Science, and Bioinformatics to assist biotech and pharma companies in optimizing their drug development processes. Physiomics has contributed to over 100 commercial projects, working with clients such as Merck KGaA, Astellas, Bicycle Therapeutics, Numab Therapeutics, and CRUK.

YTD Price Performance: -46.00%

Average Trading Volume: 4,478,475

Technical Sentiment Signal: Strong Buy

Current Market Cap: £1.23M

Find detailed analytics on PYC stock on TipRanks’ Stock Analysis page.